Median five-year data from the Phase I/II NeuVax trial released at ASCO this June showed that among node-positive patients 25.9% of the control had a recurrence, while metastases surfaced in only 5.6% of NeuVax patients. Final gold standard five-year data for all patients were released at the San Antonio Breast Cancer Symposium Dec. 5; Galena launched a Phase III trial in January 2012.

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Our monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including pharmaceuticals, medical devices, in vitro diagnostics and research/analytical instrumentation and reagents.